Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Lee, Sung-Eun  [Clear All Filters]
2024
Park S, Bang S-Y, Kwag D, Lee JHyuk, Kim TYoon, Lee J, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, et al. Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1. Bone Marrow Transplant. 2024.
2023
Jeon Y, Kim T-Y, Min GJune, Park S-S, Park S, Yoon J-H, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, et al. Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients. Cytotherapy. 2023.
Lim JUk, Park S, Yoon J-H, Lee S-E, Cho B-S, Kim Y-J, Lee S, Kim H-J, Rhee CKook. Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation. Respir Med. 2023:107410.
Min G-J, Jeon Y-W, Kim TYoon, Kwag D, Kim B-S, Lee J, Lee JHyuk, Park S-S, Park S, Yoon J-H, et al. The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma. Sci Rep. 2023;13(1):17496.
2022
Kwag D, Cho B-S, Bang S-Y, Lee JHyuk, Min G-J, Park S-S, Park S, Yoon J-H, Lee S-E, Eom K-S, et al. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J. 2022;12(12):169.
2021
Cho B-S, Yahng S-A, Min G-J, Park S, Park S-S, Shin S-H, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, et al. Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients. Transplant Cell Ther. 2021.
2020
Park S, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, Shin S-H, Yoon J-H, Lee S-E, Cho BSik, Eom K-S, et al. Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pre-transplant low WT1 expression. Biol Blood Marrow Transplant. 2020.
Lee S-E, Min GJune, Park S-S, Park S, Yoon J-H, Shin SHwan, Cho B-S, Eom K-S, Kim Y-J, Lee S, et al. Outcomes of haploidentical stem cell transplantation using total body irradiation (600 cGy) and fludarabine with ATG in adult patients with severe aplastic anemia: A prospective phase II study. Biol Blood Marrow Transplant. 2020.
2019
Lee S-E, Lim J-Y, Bin Ryu D-, Kim TWoo, Park SSoo, Jeon Y-W, Yoon J-H, Cho B-S, Eom K-S, Kim Y-J, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2019.
Cho B-S, Jeon Y-W, Hahn A-R, Lee T-H, Park S-S, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, Lee S, et al. Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. Cancer Med. 2019.
Cho B-S, Min G-J, Park S-S, Shin S-H, Yahng S-A, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, et al. WT1 measurable residual disease assay in AML who underwent allogeneic hematopoietic stem cell transplantation; optimal time points, threshold, and candidates. Biol Blood Marrow Transplant. 2019.
2018
Park S-S, Jeon Y-W, Min GJune, Park S, Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Cho B-S, Eom K-S, et al. Graft-versus-host disease free, relapse-free survival after allogeneic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018.
2015
Yoon J-H, Kim H-J, Jeon Y-W, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, Lee S, Min C-K, Cho S-G, et al. Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. Genes Chromosomes Cancer. 2015.
Lee S-E, Jo I, Jang W, Kim Y, Han K, Kim M. T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation. Ann Lab Med. 2015;35(3):376-8.
2014
Choi MHyung, Jung JIm, Chung WDo, Kim Y-J, Lee S-E, Han DHee, Ahn MIm, Park SHee. Acute Pulmonary Complications in Patients with Hematologic Malignancies. Radiographics. 2014;34(6):1755-1768.
Lee S-E, Yoon J-H, Shin S-H, Eom K-S, Kim Y-J, Kim H-J, Lee S, Cho S-G, Lee JWook, Min W-S, et al. Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biomed Res Int. 2014;2014:982504.
Lim J-Y, Lee S-E, Park G, Choi EYoung, Min C-K. Inhibition of indoleamine 2,3-dioxygenase (IDO) by stereoisomers of 1-methyl tryptophan in an experimental graft-versus-tumor model. Exp Hematol. 2014.
2013
Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Eom K-S, Kim Y-J. Acute colonic pseudo-obstruction following allogeneic stem cell transplantation successfully treated by neostigmine. Blood Res. 2013;48(2):145-8.
Eom K-S, Shin S-H, Yoon J-H, Yahng S-A, Lee S-E, Cho B-S, Kim Y-J, Kim H-J, Min C-K, Kim D-W, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013.
Min C-K, Lee S-E, Yahng S-A, Cho B-S, Eom K-S, Kim Y-J, Kim H-J, Lee S, Cho S-G, Kim D-W, et al. The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma. Blood Res. 2013;48(3):198-205.
Lee S-E, Yoon J-H, Shin S-H, Park G, Min C-K. Skin Graft-versus-host Disease Following Autologous Stem Cell Transplantation for Multiple Myeloma. Immune Netw. 2013;13(3):107-10.